Tiller J W, Maguire K P, Davies B M
Department of Psychiatry, University of Melbourne, Victoria, Australia.
Psychiatry Res. 1987 Nov;22(3):213-20. doi: 10.1016/0165-1781(87)90036-9.
Moclobemide is a reversible, short-acting monoamine oxidase inhibitor (MAO1), specific for MAO A. To study moclobemide effects on the tyramine pressor response, we gave 12 depressed patients (2 males, 10 females; mean age 47, SD 11 years) an i.v. tyramine test after 7 days drug free. The mean (+/- SD) tyramine dose to raise systolic blood pressure 30 mmHg was 5.6 +/- 2.5 mg. Repeat tyramine testing after 2 weeks of treatment with moclobemide (280 +/- 90 mg/d) showed the tyramine dose required was reduced to 2.5 +/- 1.6 mg (n = 8). The mean (+/- SD) increase in sensitivity to tyramine was 2.9 +/- 1.8. Four patients did not have repeated tyramine tests as testing was discontinued because of tyramine-induced cardiac arrhythmias. Moclobemide seems an effective antidepressant with less tyramine sensitivity than MAOIs in current use.
吗氯贝胺是一种可逆性短效单胺氧化酶抑制剂（MAO1），对MAO A具有特异性。为研究吗氯贝胺对酪胺升压反应的影响，我们对12例抑郁症患者（2例男性，10例女性；平均年龄47岁，标准差11岁）在停药7天后进行静脉注射酪胺试验。使收缩压升高30 mmHg的平均（±标准差）酪胺剂量为5.6±2.5 mg。在用吗氯贝胺（280±90 mg/d）治疗2周后重复酪胺试验，结果显示所需酪胺剂量降至2.5±1.6 mg（n = 8）。对酪胺敏感性的平均（±标准差）增加为2.9±1.8。4例患者未进行重复酪胺试验，因为由于酪胺诱发的心律失常而停止了试验。吗氯贝胺似乎是一种有效的抗抑郁药，与目前使用的单胺氧化酶抑制剂相比，对酪胺的敏感性较低。
